Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa crossover PK study of nebulised RPL554 in adult cystic fibrosis patients
2015-004263-36Phase 2Terminated
- Sponsor
- Verona Pharma
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing RPL554 arm with Placebo arm (2 arms). Primary endpoint: RPL554 pharmacokinetic parameters. Started Aug 2016; status: terminated.
02
Drugs
ensifentrine
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-004263-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004263-36.